Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

Scalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...